Whilst the TCHL trial has a relatively small number of participants, its data strongly correlate with recently published clinical data, and suggest that anti-HER2 TKIs merit further investigation in the neo-adjuvant treatment of low-risk early stage breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.